There are no approved treatments for Lewy body dementia, the second most common cause of neurodegenerative dementia.
And there is an urgent need to find therapies for this and related disorders such as Alzheimer’s disease.
In a recent study at the University of North Carolina at Chapel Hill, researchers found that people with mild-to-moderate Lewy body dementia (LBD) had a big improvement in cognition when they took the drug neflamapimod three times daily.
The finding from the trial of neflamapimod in dementia with Lewy bodies is very encouraging.
One researcher of the study is Jeffrey L. Cummings, MD, ScD.
As a Lewy Body Dementia Association (LBDA) Center of Excellence, UNC Neurology served as one of the phase 2 study sites.
The team is expected to be included as a study site for the planned phase 3 clinical trial.
They say the exciting results of the phase 2 study showing the benefit of the new drug neflamapimod for cognition in dementia with Lewy bodies will bring hope to patients and their caregivers.
If these findings are confirmed in a phase 3 study, the potential impact for patients with dementia with Lewy bodies will be significant.
Copyright © 2021 Knowridge Science Report. All rights reserved.
